Summary: At Psych Congress 2024, Axsome Therapeutics will present new research on solriamfetol, focusing on its effectiveness for managing excessive daytime sleepiness and cognitive impairment in patients with obstructive sleep apnea (OSA) and narcolepsy. These studies, part of … [Read more...]
Axsome to Present Data on AXS-12 and Solriamfetol at Sleep Europe 2024
Summary: Axsome Therapeutics In. is set to present multiple studies on AXS-12 and solriamfetol at Sleep Europe 2024, the 27th Congress of the European Sleep Research Society. These presentations include topline results from the phase 3 SYMPHONY trial of AXS-12 for narcolepsy, … [Read more...]